CST, 2099S, ADAM9 Antibody

Polyclonal Antibody for studying ADAM9. Validated for Western Blotting,Immunoprecipitation. Highly specific and rigorously validated in-house, ADAM9 Antibody (CST #2099) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:100 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity ADAM9 Antibody detects endogenous levels of total ADAM9 protein, unprocessed and active forms. This antibody does not recognize the carboxy terminally truncated short form of ADAM9. In some cell types, this antibody cross-reacts with a 50 kDa band of unknown origin. Species Reactivity: Human, Mouse, Rat, Monkey Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the carboxy terminus of human ADAM9. Antibodies are purified using protein A and peptide affinity chromatography. Background The ADAM (A Disintegrin and A Metalloprotease) family of multidomain membrane proteins influences cell signaling and adhesion by shedding cell surface proteins such as cytokines and growth factors, by influencing cell adhesion to the extracellular matrix (ECM), and by directly remodeling the ECM. Conserved domains in ADAM family members include a prodomain, a zinc-dependent metalloprotease domain, a disintegrin domain, a cysteine-rich domain, an EGF-like sequence, and a short cytoplasmic tail (1,2).The prodomain is thought to aid in protein folding. Disintegrin and cysteine-rich domains mediate adhesion, at least in part, through binding to integrins. Phosphorylation of the cytoplasmic tail as well as its interaction with other signaling proteins may influence intra- and extracellular signaling (1). ADAM9 is widely distributed and has been shown to affect migration in skin keratinocytes (3,4). Research studies have shown that ADAM9 is overexpressed in prostate cancer (5), pancreatic cancer (6), gastric cancer (7), and has been linked to invasion and metastasis in small cell lung cancer (8). Research has also shown that an alternatively spliced short (50 kDa) form of ADAM9 containing protease activity is involved in tumor cell invasion (9). Alternate Names a disintegrin and metalloproteinase domain 9 (meltrin gamma); ADAM 9; ADAM metallopeptidase domain 9; ADAM metallopeptidase domain 9 (meltrin gamma); ADAM9; Cellular disintegrin-related protein; cone rod dystrophy 9; CORD9; Disintegrin and metalloproteinase domain-containing protein 9; KIAA0021; MCMP; MDC9; Meltrin-gamma; Metalloprotease/disintegrin/cysteine-rich protein 9; MLTNG; Myeloma cell metalloproteinase Specification REACTIVITY: H M R Mk SENSITIVITY: Endogenous MW (kDa): 100 pro-ADAM9-L, 80 ADAM9-L SOURCE: Rabbit